Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

t," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.

Mr. Bienaime continued, "As of October 24, 208 patients have been referred through the Kuvan free drug program, including patients in the pilot program. We are supporting a number of investigator-sponsored trials to generate additional data to support the use of Kuvan, as well as various patient communication and online efforts. Also, our partner Merck Serono received a positive CHMP opinion for Kuvan in late September which bodes well for potential approval by the end of the year. We are well on our way to achieving our first fully profitable year with a strong cash position and a full development pipeline. Going forward, we remain focused on the Kuvan launch, the continued geographic expansion of Naglazyme, and the timely development of the PEG-PAL, GALNS for MPS IVA and other promising pipeline programs."

Net Product Revenue

Net product revenue from Naglazyme (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), was $33.3 million for the third quarter of 2008, an increase of 56.3 percent compared to Naglazyme net product revenue of $21.3 million for the third quarter of 2007. Net product revenue from Naglazyme for the nine months ended September 30, 2008 was $96.2 million, an increase of 58.7 percent from Naglazyme net product revenue of $60.6 million for the nine months ended September 30, 2007. BioMarin is directly commercializing Naglazyme in the United States, Western Europe, Brazil, and Turkey and through distributors in other international markets.

Net sales of Aldurazyme (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I (MPS I) recorded by Genzyme, were $38.2 million for the third quarter of 2008, an increase of 18.3 percent compared to net sales by Genzyme of $32.3 million for the third quarter of 2007. Net sales of Aldurazyme recorded by Genzyme for the nine months ended September 30, 2008 were $113.7 million
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... April 3, 2008 Alba Therapeutics Corporation,today announced ... Chief Executive,Officer (CEO) and a member of its ... with SV Life Sciences Advisors, LLC. Previously, he ... the senior management team for several,successful entrepreneurial healthcare ...
... A policy comment in Science,today quotes Genelex out ... claims about the utility of CYP450,testing for particular ... testing is "required to effectively prescribe Paxil",( http://www.healthanddna.com/professional/paxil.html ... (paroxetine) is metabolized through CYP2D6. Pharmacogenetic,testing of this ...
... Term Development Agreement to Produce Reference Standard Reagents to ... ... 2008 Strategic,Diagnostics Inc. (Nasdaq: SDIX ) -- a ... sciences industry announced that it has,been selected by Science Applications ...
Cached Biology Technology:Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer 2Science Fuels DNA Testing Controversy with Prejudicial Misquote 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 3
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve been here ... but can,t remember your password, site key or the answer to ... grade teacher? Today, Hoyos Labs , a ... finally put an end to the frustration that comes with usernames, ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist Medical ... for its School of Medicine. Funding for this $50 million ... will be publicly launched next summer. The ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ...
(Date:12/10/2014)... Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) has announced the ... report to their offering. ... and smart cards for projects such as rural banking ... the major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... WI, NOVEMBER 17, 2008 Global land use patterns ... urban stormwater management. Traditional stormwater management focuses on ... generally does little to restore the hydrologic cycle ... with low permeability. The lack of infiltration opportunities ...
... Mellon University,s Robotics Institute have received a total of ... Agriculture (USDA) to build automated farming systems. One is ... but both are designed to improve fruit quality and ... autonomous robotic vehicles or at fixed sites within the ...
... team of researchers led by investigators at the Albert ... that certain commonly-prescribed medications may have the unintended consequence ... finding could alter the way doctors prescribe migraine medicines. ... Headache , the Einstein-led study of more than ...
Cached Biology News:Urban trees enhance water infiltration 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 3Overuse of narcotics and barbiturates may make migraine worse 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: